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Background: While a great deal of work has gone into understanding the relationship
between Cerebrospinal fluid (CSF) biomarkers, brain atrophy, and disease progression,
less work has attempted to investigate how genetic variation modifies these relationships.
The goal of this study was two-fold. First, we sought to identify high-risk vs. low-risk
individuals based on their CSF tau and Aβ load and characterize these individuals with
regard to brain atrophy in an AD-relevant region of interest. Next, we sought to identify
genetic variants that modified the relationship between biomarker classification and
neurodegeneration.
Methods: Participants were categorized based on established cut-points for biomarker
positivity. Mixed model regression was used to quantify longitudinal change in the left
inferior lateral ventricle. Interaction analyses between single nucleotide polymorphisms
(SNPs) and biomarker group status were performed using a genome wide association
study (GWAS) approach. Correction for multiple comparisons was performed using the
Bonferroni procedure.
Results: One intergenic SNP (rs4866650) and one SNP within the SPTLC1 gene
(rs7849530) modified the association between amyloid positivity and neurodegeneration.
A transcript variant of WDR11-AS1 gene (rs12261764) modified the association between
tau positivity and neurodegeneration. These effects were consistent across the two
sub-datasets and explained approximately 3% of variance in ventricular dilation. One
additional SNP (rs6887649) modified the association between amyloid positivity and
baseline ventricular volume, but was not observed consistently across the sub-datasets.
Conclusions: Genetic variation modifies the association between AD biomarkers and
neurodegeneration. Genes that regulate the molecular response in the brain to oxidative
stress may be particularly relevant to neural vulnerability to the damaging effects of
amyloid-β.
Keywords: Alzheimer’s disease (AD), MRI, CSF biomarkers, gene-environment interaction, genomics, amyloid, tau
proteins
INTRODUCTION
Competing models of the sporadic Alzheimer’s disease (AD) cas-
cade have debated whether the two primary pathologies, amyloid-
beta (Aβ) plaques and tau neurofibrillary tangles, are causally
related, with some suggesting that early amyloid pathology drives
later tau pathology and others suggesting both pathologies arrive
through distinct, unrelated molecular pathways (Small and Duff,
2008; Jack et al., 2010, 2013). In either case, it is theorized that
the onset of these protein pathologies ultimately drives synaptic
changes and the neurodegenerative cascade resulting in cognitive
impairment.
Cerebrospinal fluid (CSF) measures of pathology in vivo have
been applied alongside magnetic resonance imaging (MRI) to
elucidate the relation between biomarkers of pathology and neu-
rodegeneration and as combined measures of risk for disease
onset and progression. To date, higher levels of CSF tau and
lower levels of CSF Aβ have been shown to predict decreases in
total and regional brain volume longitudinally, though regional
patterns of atrophy appears to vary across diagnostic categories
(Tosun et al., 2010). Other results have suggested that decreased
CSF Aβ levels are related to atrophy rates in healthy nor-
mal adults (Fagan et al., 2009; Fjell et al., 2010; Schott et al.,
2010), whereas either biomarker can predict atrophy in Mild
Cognitive Impairment (MCI) and AD (Sluimer et al., 2010).
Parallel research has demonstrated that the combined diagnos-
tic utility of both CSF and MRI biomarkers is greater than
either measure independently (Vemuri et al., 2009a,b; Sluimer
et al., 2010; Davatzikos et al., 2011). Moreover, both CSF
and MRI biomarkers appear to provide independent contribu-
tions to AD diagnosis, further suggesting each marks a distinct
biological process in the AD cascade (Schoonenboom et al.,
2008).
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While a great deal of work has gone into understanding the
relationship between CSF biomarkers, brain atrophy, and dis-
ease progression, few studies have attempted to investigate how
genetic variation modifies these relationships. One possibility is
that single genes are associated with biomarker load. Indeed,
previous work has demonstrated a relationship between CSF
Aβ and the APOE genotype (Morris et al., 2010), and more
recently genome-wide association studies (GWAS) have identi-
fied genetic variants that are related to CSF biomarkers (Kim
et al., 2011). A second possibility is that genes interact to con-
fer risk or resilience from biomarker load. Work in our lab has
identified novel gene-gene interactions that are related to Aβ
load as measured with positron emission tomography (PET)
(Hohman et al., 2013, 2014b; Koran et al., 2014b) and brain
atrophy measured with MRI (Meda et al., 2013; Koran et al.,
2014a). A final possibility is that genes interact with the pres-
ence of biomarkers to confer risk or resilience from longitudinal
changes in brain volume or cognition. In one study, the APOE
genotype in combination with biomarker positivity (high CSF
tau or low CSF Aβ-42) at baseline was associated with increased
regional atrophy in MCI subjects; however, the authors reported
that no biomarker × APOE interaction reached statistical sig-
nificance (Tosun et al., 2010). We previously identified an inter-
action between CSF levels of phosphorylated tau (ptau) and
variation in the protection of telomeres 1 (POT1) gene that mod-
ified the association between ptau load and neurodegeneration
(Hohman et al., 2014a). Yet, no study to date has systematically
approached genetic modification of the relationship between CSF
biomarkers of protein pathology and MRI biomarkers of disease
progression.
The goal of this study was to identify genetic variants that
modified the relationship between biomarker classification and
neurodegeneration. We hypothesized we would identify a sub-
set of individuals who were resilient to the neurodegenerative
cascade associated with biomarker positivity based on genotypic
variation across the sample. Moreover, we hypothesized that such
variation would explain variance in brain atrophy above and
beyond the effect of the APOE genotype. The identification of
such genetic factors could clarify the mechanistic relationship
between CSF biomarkers and neurodegeneration and provide tar-
gets for clinical intervention aimed at altering such pathways of
neuro-vulnerability.
MATERIALS AND METHODS
Data used in the preparation of this article were obtained from the
Alzheimer’s Disease Neuroimaging Initiative (ADNI) database
(adni.loni.usc.edu). The ADNI was launched in 2003 by the
National Institute on Aging (NIA), the National Institute of
Biomedical Imaging and Bioengineering (NIBIB), the Food and
Drug Administration (FDA), private pharmaceutical companies
and non-profit organizations, as a $60 million, 5-years public-
private partnership. The primary goal of ADNI has been to test
whether serial MRI, PET, other biological markers, and clinical
and neuropsychological assessment can be combined to measure
the progression of MCI and early AD. Determination of sensi-
tive and specific markers of very early AD progression is intended
to aid researchers and clinicians to develop new treatments and
monitor their effectiveness, as well as lessen the time and cost of
clinical trials.
The Principal Investigator of this initiative is Michael
W. Weiner, MD, VA Medical Center and University of
California – San Francisco. ADNI is the result of efforts of many
co-investigators from a broad range of academic institutions and
private corporations, and subjects have been recruited from over
50 sites across the U.S. and Canada. The initial goal of ADNI was
to recruit 800 subjects, but ADNI has been followed by ADNI-GO
and ADNI-2. To date these three protocols have recruited over
1500 adults, ages 55–90, to participate in the research, consist-
ing of cognitively normal older individuals, people with early or
late MCI, and people with early AD. The follow up duration of
each group is specified in the protocols for ADNI-1, ADNI-2 and
ADNI-GO. Subjects originally recruited for ADNI-1 and ADNI-
GO had the option to be followed in ADNI-2. For up-to-date
information, see www.adni-info.org.
SUBJECTS
Participants were enrolled based on criteria outlined in
the ADNI protocol (http://www.adni-info.org/scientists/ADNI
StudyProcedures.aspx). To avoid spurious genetic effects due
to population stratification, only Caucasian participants were
used in analyses. Demographic data are presented in Table 1.
All analyses were performed in the combined dataset which
includes participants in both the ADNI-1 and ADNI-2/GO proto-
cols. ADNI and ADNI-2/GO were approved by the Institutional
Review Boards of all of the participating institutions. Informed
written consent was obtained from all participants at each site.
All data analyzed herein were de-identified and all analyses were
deemed exempt by the Vanderbilt IRB per 45 CFR 46.101(b).
GENOTYPING
In ADNI-1, genotyping was performed using the Illumina
InfiniumHuman-610-Quad BeadChip. In ADNI-2/GO, genotyp-
ing was performed on the Illumina OmniQuad array. Quality
control (QC) and statistical analyses were performed using
PLINK software (version 1.07; Purcell et al., 2007). During
QC, we excluded Single Nucleotide Polymorphisms (SNPs)
with a genotyping efficiency <90%, a minor allele frequency
(MAF) < 5%, or deviation from Hardy-Weinberg Equilibrium
(p < 1 × 10−6). This left 515,383 SNPs in ADNI-1 and 605,317
SNPs in ADNI-2/GO. Finally, we merged the two genotyping files
for our analyses and again applied a genotyping efficiency<90%.
This left a total of 296,267 SNPs for data analysis.
QUANTIFICATION OF VENTRICULAR DILATION
We used all FreeSurfer data from 1.5 Tesla scans across ADNI-1,
ADNI-GO, and ADNI-2 in our analyses by merging the publicly
available FreeSurfer data for the two cohorts. Cortical recon-
struction and volumetric segmentation were performed with
the FreeSurfer image analysis suite version 4.3 (http://surfer.
nmr.mgh.harvard.edu/; Dale et al., 1999; Fischl et al., 1999a,b).
FreeSurfer processing in ADNI has been described in detail else-
where (Mormino et al., 2009). An early version of the longitudinal
image processing framework was used to process the sequential
scans (Reuter et al., 2012). We used the change in volume of
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Table 1 | Sample characteristics.
Baseline clinical diagnosisa
Normal control Mild cognitive impairment Alzheimer’s disease
A
D
N
I-1
da
ta
se
t
Number of patients 102 176 92
Number of APOE-ε4 carriers 23 97 63
Number of females 48 59 39
Mean baseline age (SD) 75.75 (4.99) 74.61 (7.59) 74.97 (7.93)
Mean years of education (SD) 15.92 (2.71) 15.75 (3.01) 15.23 (3.20)
Mean number of visits 5.09 (1.42) 5.16 (1.74) 3.33 (0.89)
Mean interval in days 1320 (549) 1034 (544) 582 (252)
Number tau positive (%) 22 (22) 80 (35) 62 (67)
Number amyloid positive (%) 40 (39) 131 (74) 85 (92)
A
D
N
I-2
/G
O
da
ta
se
t
Number of patients 92 206 22
Number of APOE-ε4 carriers 21 89 14
Number of females 45 92 9
Mean baseline age (SD) 74.68 (5.68) 71.41 (7.30) 75.55 (10.53)
Mean years of education (SD) 16.40 (2.55) 15.94 (2.69) 15.45 (2.82)
Mean number of visits 3.55 (1.03) 3.94 (0.89) 3.41 (0.91)
Mean interval in days 365 (152) 471 (203) 310 (146)
Number tau positive (%) 22 (24) 72 (35) 17 (77)
Number amyloid positive (%) 25 (27) 93 (45) 20 (91)
C
om
bi
ne
d
da
ta
se
t
Number of patients 194 382 114
Number of APOE-ε4 carriers 44 186 77
Number of females 93 151 48
Mean baseline age (SD) 75.24 (5.34) 72.88 (7.60) 75.08 (8.44)
Mean years of education (SD) 16.15 (2.64) 15.85 (2.84) 15.27 (3.12)
Mean number of visits 4.36 (1.46) 4.50 (1.48) 3.34 (0.89)
Mean interval in days 867 (630) 730 (487) 529 (258)
Number tau positive (%) 44 (23) 152 (40) 79 (69)
Number amyloid positive (%) 65 (33) 224 (59) 105 (92)
aNormal Control subjects had a Mini-Mental Status Examination (MMSE) score between 24 and 30, a Clinical Dementia Rating (CDR) score of 0, and were not
depressed (Geriatric Depression Scale score < 6). Mild Cognitive Impairment subjects had a MMSE score between 24 and 30, objective memory impairment,
subjective memory impairment, and a CDR score of 0.5. Alzheimer’s Disease subjects met clinical criteria for dementia, had an MMSE of between 20 and 26, and
had CDR score of 0.5 or 1.
the left inferior lateral ventricle as our primary outcome mea-
surement and included a measurement of intracranial volume
(ICV) as a covariate in all volumetric analyses; both of which were
defined in FreeSurfer (Desikan et al., 2006). Slopes of change in
left ventricular volume over time were calculated in SAS 9.3 (SAS
Institute Inc., Cary, NC) using mixed model regression (PROC
MIXED) to leverage the longitudinal data available. A conven-
tional mixed model was used that included the fixed effect of time
(fraction of years from baseline) and the intercept, as well as a
random effect for time and the intercept. In such a model, the
assumption is that individual slopes are normally distributed with
the fixed effect of time representing the mean, and the variance
represented in the random effect. On average we had four MRI
scans for each subject. More details on the longitudinal data are
presented in Table 1.
BIOMARKER GROUPS
CSF biomarker quantification in ADNI was performed previously
(Shaw et al., 2011), and detailed processing steps are available
elsewhere (Jagust et al., 2009). The present dataset was compiled
across UPENN1—UPENN5 data sources available for download
from the ADNI site. We made use of the first available measure
of Aβ-42 and total tau for each subject. The first observation
for all ADNI-2/GO subjects came from the UPENN5 dataset;
while the first observation for all ADNI-1 subjects came from
the UPENN1 dataset. Three subjects in ADNI-1 did not have a
useable observation in the UPENN1 dataset, so we used the first
observation available from the other UPENN datasets. Subjects
were classified into four groups based on previously defined
cut-off points (Jagust et al., 2009): amyloid positive (Aβ − 42 ≤
192), tau positive (tau ≥ 93), both amyloid and tau positive,
or both amyloid and tau negative. We chose to use t-tau rather
than p-tau in our biomarker groups because t-tau showed bet-
ter sensitivity and specificity in the report establishing these cuts
points (Jagust et al., 2009). Of the 690 participants analyzed,
234 were amyloid and tau negative, 160 were amyloid posi-
tive, 41 were tau positive, and 255 were both amyloid and tau
positive.
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STATISTICAL ANALYSES: BIOMARKER GROUPS IN RELATION TO
BRAIN VOLUME
Statistical analysis was performed using SPSS v. 22 (http://
www-01.ibm.com/software/analytics/spss/). General linear
model (GLM) was used to test the relation between biomarker
groups and left inferior lateral ventricle volume (LILV). Past work
has demonstrated that, when measured longitudinally, the LILV
shows greater dilation than the right, both in AD patients and
in controls (Thompson et al., 2004). We have also successfully
applied this variable as a quantitative outcome in previous genetic
interaction analyses (Hohman et al., 2014a; Koran et al., 2014a).
LILV slopes were set as the quantitative outcome and biomarker
group status was dummy coded where biomarker negative was
set as the reference category. Sex, diagnosis, age, education, ICV,
and APOE genotype (coded as carriers vs. non-carriers of the ε4
allele) were entered into the model as covariates.
STATISTICAL ANALYSES: GENETIC INTERACTIONWITH BIOMARKER
GROUP
Genetic interaction analyses were performed using the—linear
command in PLINK. A dominant model was used for gene cod-
ing (0—no minor allele present, 1—minor allele present). The
dominant model was selected to reduce the risk of spurious asso-
ciations due to low contingency table cell counts when evaluating
the biomarker group × SNP interaction. The same covariates
were used for all genetic analyses; however, we excluded the
APOE genotype at this stage in order to maximize our power
to identify novel SNP effects. Biomarker groups were dummy
coded with “biomarker negative” set as the reference category
(LILV Slope = β0 + β1 Baseline_Age + β2 Baseline_ICV + β3
Gender + β4 Education + β5 Dx + β6 Tau_Positive + β7
Amyloid_Positive + β8 Tau_and_Amyloid_Positive + β9 SNP +
β10 SNP∗Tau_Positive + β11 SNP∗Amyloid_Positive + β12
SNP∗Tau_and_Amyloid_Positive). β10−12 were the terms of
interest, and correction for multiple comparisons was per-
formed for the total number of SNPs tested (296,109) using the
Bonferroni procedure (cut-off p-value = 1.86 × 10−7). Next, the
“Tau_and_Amyloid_Positive” term as removed from the model
so that we could investigate SNPs that modify the relationship
between these pathologies irrespective of the presence of the other
pathology. In this case the amyloid term was coded as positive
or negative, and the tau term was coded as positive or negative.
Again, correction for multiple comparisons was performed using
the Bonferroni procedure. Finally, these same two models were
evaluated for SNP × biomarker interactions on baseline brain
volume by setting baseline LILV as the quantitative outcome.
Although we do not have an independent replication sam-
ple with CSF data, MRI data, and genotype data, we chose to
evaluate the consistency of our signal across datasets in order to
provide some preliminary validation of our findings. The sample
was divided into ADNI-1 and ADNI-2/GO based on the genotype
chip used (Table 1), and significant interactions were re-evaluated
within each cohort using the same covariates outlined above.
POST-HOC ANALYSES: HIERARCHICAL LINEAR REGRESSION
Following genetic interaction analyses, hierarchical linear regres-
sion was performed in SPSS 22 in order to calculate the amount
of variance explained by these novel genetic interactions above
and beyond known predictors of brain volume and the APOE
genotype. The first step in the model included sex, education,
diagnosis, age, ICV, diagnosis, and biomarker group. Next, APOE
genotype was inserted into the model. Third, the SNP term was
inserted into themodel. Finally, the SNP× Biomarker group term
was added into the model. Change in R square was calculated at
each step of the regression model.
RESULTS
BIOMARKER GROUPS IN RELATION TO BRAIN VOLUME
As expected, biomarker group was associated with LILV slope
when controlling for the covariates outlined above, [F(3, 679) =
6.50, p = 0.0002]. As shown in Figure 1, amyloid positivity alone
(t = 4.144, p = 0.00003) and combined amyloid/tau positivity
(t = 2.83, p = 0.005) were associated withmore rapid ventricular
dilation relative to biomarker negativity, while tau positivity alone
was not associated with a faster ventricular dilation (t = −0.22,
p = 0.825). At baseline, biomarker group was also associated
with LILV volume when controlling for the same variables
[F(3, 681) = 4.69, p = 0.003]. However, only amyloid positivity
alone significantly differed from the biomarker negative group
when controlling for multiple comparisons (t = 3.46, p = 0.003;
Supplemental Figure 4). When modeling tau or amyloid positiv-
ity irrespective of the presence of the other biomarker (removing
the “both” term from the model), only the amyloid term was
associated with ventricular dilation (t = 4.38, p = 1 × 10−5).
FIGURE 1 | Amyloid positivity and combined biomarker positivity
predict ventricular dilation. Biomarker groups are along the x-axis and
annual change in left inferior lateral ventricle volume is on the y axis. The
groups differ in their mean annual change, [F(3, 679) = 6.50, p = 0.0002],
with the amyloid positivity alone (t = 4.144, p = 0.00003) and the
combined amyloid/tau positivity (t = 2.83, p = 0.005) groups showing
significant deviation from the biomarker negative referent group.
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GENETIC INTERACTION ANALYSIS
When using the four group coding scheme (both positive, amy-
loid positive, tau positive, both negative), one SNP × Amyloid
interaction showed an association with baseline ventricular vol-
ume: the intergenic SNP rs6887649 (MAF = 5%); however, this
effect was not consistent across the ADNI-1 and ADNI-2/GO
datasets (Table 2). Minor allele carriers showed larger ventri-
cles at baseline in the amyloid positive group (Supplemental
Figure 1). Two SNP × Amyloid interactions showed an associ-
ation with longitudinal change in ventricular volume: the inter-
genic SNPs rs7849530 (MAF = 12%) and rs4866650 (MAF =
6%). Additional details of these results are presented in Table 2.
These interactions remained statistically significant when correct-
ing for MRI processing batch (p < 1.86×10−7). In both cases the
presence of the minor allele was associated with faster dilation of
the ventricles in amyloid positive individuals (Figures 2, 3).
We also tested whether the peak observed interaction was clin-
ically meaningful by testing whether it was associated with disease
status as a binary outcome (rather than the quantitative outcome
used in our original analyses). Indeed, the rs7849530 × amyloid
interaction showed an association with disease status in a binary
logistic regression with the same covariates used in the previous
analyses (OR = 3.294, p = 0.046) suggesting that this interaction
is also associated with clinical status.
When using the second coding scheme (biomarker negative,
tau positive, amyloid positive), no SNP × biomarker interac-
tions were associated with baseline ventricular volume, however
one SNP × Tau interaction showed an association with longitu-
dinal change in ventricular volume: rs12261764 (MAF = 21%)
annotated toWDR11-AS1. In this case, the minor allele was asso-
ciated with slower dilation in tau positive individuals, and faster
dilation in tau negative individuals (Figure 4), although only the
difference in tau positive individuals showed consistency across
the two ADNI subsets (Figure 5). This interaction also remained
statistically significant when correcting for MRI processing batch
(p < 1.86 ×10−7).
POST-HOC ANALYSIS: HIERARCHICAL LINEAR REGRESSION
Results are presented in Table 3. The first step in the hierar-
chical linear regression model explained 35.2% of the variance
in LILV slope. In terms of the adjusted-R2, APOE genotype
explained an additional 0.2% of variance. Rs7849530 explained an
additional 1.9% of the variance, and the rs7849530 × biomarker
group interaction terms explained an additional 3.5% of the
variance. Similarly, rs4866650 explained 1.4% of variance and
the rs4866650 × biomarker group interaction terms explained
an additional 3.2% of variance. When using the second coding
FIGURE 2 | SPTLC1 (rs7849530) modifies the association between
amyloid positivity and ventricular dilation. Biomarker groups are
presented on the x-axis and annual change in the left inferior lateral ventricle
is presented on the y-axis. Boxplots are grouped by rs7849530. G is the
minor allele. When controlling for Age, Gender, Education, Diagnosis, and
ICV, the amyloid_positive × rs7849530 interaction was statistically
significant (t = 6.39, p = 3.14 × 10−10). In the amyloid-only biomarker
group, carriers of the G allele showed a greater rate of ventricular dilation
than homozygous carriers of the A allele (t = 5.306, p < 0.001). Model:
LILV Slope = β0 + β1Baseline_Age + β2Baseline_ICV + β3Gender +
β4Education + β5Dx + β6Tau_Positive + β7Amyloid_Positive +
β8Tau_and_Amyloid_Positive + β9SNP + β10SNP∗Tau_Positive +
β11SNP∗Tau_and_Amyloid_Positive + β12SNP∗Amyloid_Positive.
Table 2 | SNP interaction results.
SNP ADNI-1 dataset ADNI2/GO dataset Combined datasets
t p-value t p-value t p-value
AMYLOID INTERACTIONS ON INTERCEPT
rs6887649 (FTMT ) 4.95 1.50 ×10−6 −0.13 0.899 5.68 1.99 ×10−8*
AMYLOID INTERACTIONS ON SLOPE
rs7849530 (SPTLC1) 4.52 8.00 ×10−6 2.64 0.009 6.40 2.89 ×10−10*
rs4866650 3.89 0.0001 2.28 0.023 6.15 1.35 ×10−9*
TAU INTERACTIONS ON SLOPE
rs12261764 (WDR11-AS1) 4.54 8.00 ×10−6 3.18 0.002 5.55 9.5 ×10−8*
*Significant when correcting for multiple comparisons (Bonferroni < 0.05).
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FIGURE 3 | SPTLC1 (rs7849530) interaction is consistent between
datasets. ADNI-1 data are presented in the top panel. ADNI-2/GO
data are presented in the bottom panel. Biomarker groups are
presented on the x-axis and annual change in the left inferior lateral
ventricle is presented on the y-axis. Boxplots are grouped by
rs7849530. G is the minor allele. The amyloid × rs7849530
interaction was statistically significant in both datasets (p < 0.01), and
in both cases amyloid positive carriers of the G allele showed a
greater rate of ventricular dilation than amyloid positive homozygous
carriers of the A allele (p < 0.01).
scheme (biomarker negative, tau positive, amyloid positive) the
first step in linear regression model explained 35.7% of vari-
ance. APOE genotype explained 0.2% of variance. Rs12261764
explained less than 0.01% of variance alone, but the rs12261764
× biomarker interaction terms explained an additional 2.7% of
variance.
DISCUSSION
Consistent with previous reports (Fjell et al., 2010), we found
that amyloid positivity was a strong predictor of longitudinal
change in ventricular volume, while tau positivity alone was
not. Moreover, we have identified four SNPs that modify the
association between biomarker positivity and neurodegeneration.
These results suggest that genetic variation may alter individ-
ual susceptibility to the damaging effects of AD neuropathology,
although future studies are needed to replicate the observed
genetic interactions.
BIOMARKER GROUPS AND LONGITUDINAL VENTRICULAR DILATION
We observed an association between biomarker group and left
ventricular dilation in which amyloid positivity alone or in com-
bination with tau positivity was associated with longitudinal
brain atrophy. This finding is consistent with previous reports,
particularly in the inferior lateral ventricles, in which stronger
associations have been observed between amyloid positivity and
ventricular volume (Olt et al., 2010) and ventricular dilation
(Fjell et al., 2010), while tau did not show this association.
This observation is also consistent with the proposed cascade
of AD biomarkers in which amyloid shows the earliest changes
in biomarker levels, followed by tau (Jack et al., 2013). Thus,
the observed association between the amyloid-only and the both
biomarker group with brain volume change in an AD relevant
region of interest is consistent with the expected AD cascade.
The exact relation between CSF biomarkers and both cross-
sectional and longitudinal brain volume appears to vary by brain
region and is modified by genetic profile (Tosun et al., 2010).
Thus, additional analyses targeting non-AD regions of interest,
or performed at a voxel-wise level, may help further clarify the
association between brain atrophy and biomarker status. Given
the association also varies by diagnosis (Tosun et al., 2010), larger
samples that allow stratification across diagnostic groups will be
needed to fully evaluate potential genetic modifiers of this com-
plex relationship. Regardless, the available data allowed us to
pursue genetic modifiers of the association between biomarker
status and brain volume and led to a few interesting interactions
we will now discuss in detail.
SNPs MODIFY THE ASSOCIATION BETWEEN AMYLOID POSITIVITY
AND VENTRICULAR VOLUME
One SNP modified the association between amyloid positivity
and ventricular volume at baseline (rs6887649). This intergenic
SNP is 3 KB from a cluster of SNPs that have been associated
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FIGURE 4 | WDR11-AS1 (rs12261764) modifies the association between
Tau positivity and ventricular dilation. Biomarker groups are presented
on the x-axis and annual change in the left inferior lateral ventricle is
presented on the y-axis. Boxplots are grouped by rs12261764. G is the
minor allele. When controlling for Age, Gender, Education, Diagnosis, and
ICV, the tau_positive × rs12261764 interaction was statistically significant
(t = 5.55, p = 4.06 × 10−8). In the tau positive biomarker group,
homozygous carriers of the G allele showed a greater rate of ventricular
dilation than carriers of the T allele (t = 2.18, p = 0.030). In the tau negative
biomarker group, homozygous carriers of the G allele showed a slower rate
of ventricular dilation than carriers of the T allele (t = 2.21, p = 0.027).
Model: LILV Slope = β0 + β1Baseline_Age + β2 Baseline_ICV + β3 Gender
+ β4 Education + β5Dx + β6Tau_Positive + β7Amyloid_Positive + β8SNP +
β9SNP∗Amyloid_Positive + β10SNP∗Tau_Positive.
with HDL-cholesterol levels in a recent GWAS (Kathiresan et al.,
2007). This SNP is also 10KB upstream of ferritin mitochon-
drial gene (FTMT). Interestingly, FtMt has been recently been
implicated as a neuroprotective factor in neurodegenerative dis-
ease through regulation of iron homeostasis in the brain (Gao
and Chang, 2014). Moreover, it has been specifically implicated in
reducing oxidative damage and reducing β-amyloid-induced neu-
rotoxicity (Wu et al., 2013). Our findings further implicate FtMt
in AD pathogenesis, although a larger sample is needed to ver-
ify this effect, particularly given that the effect was not observed
consistently between the ADNI-1 and ADNI-2/GO datasets.
Two SNPs were identified that modified the association
between amyloid positivity and ventricular dilation (rs7849530
and rs4866650). In both cases these effects were consistent across
the ADNI-1 and ADNI-2/GO cohorts, validating the association
and suggesting the effect may indeed replicate in an indepen-
dent sample. Interestingly, both of these SNPs are also within
50 kb of SNPs that have shown weak associations with AD pre-
viously (Li et al., 2008). Additionally, the rs7849530 × amyloid
interaction showed an association with disease status in a binary
logistic regression with the same covariates used in the previous
model. As with brain volume, the minor allele at rs7849530 was
protective in non-amyloid positive individuals and conferred risk
in amyloid positive individuals.
Rs7849530 is 50 kb upstream of serine palmitoyltransferase,
long chain base subunit 1 (SPTLC1). Interestingly, ceramide lev-
els, both in the brain and the blood, have been associated with
risk for AD in a number of studies (Satoi et al., 2005; Filippov
et al., 2012; Mielke et al., 2012). Serine palmitoyltransferase is
the rate limiting enzyme in ceramide synthesis, and SPTLC1
has been specifically implicated in increased ceramide synthe-
sis triggering apoptosis in Hereditary Sensory Neuropathy type
1 (HSN1) cells (Dawkins et al., 2001). Moreover, Aβ induced
membrane oxidative stress has been shown to cause ceramide
accumulation to increase, ultimately resulting in apoptosis and
neurodegeneration (Cutler et al., 2004). The present results sug-
gest that genetic variation associated with ceramide synthesis
may leave individuals vulnerable to neurodegeneration in the
presence of amyloid, perhaps due to the previously identified rela-
tion between Aβ induced oxidative stress and ceramide-induced
apoptosis.
It is quite interesting that the higher rate of ventricular dila-
tion in minor allele carriers of rs7849530 and rs4866650 is only
observed in the group that is amyloid positive (only), but not
in the group that is both amyloid and tau positive. In the cur-
rent analyses we used baseline biomarker groups to predict future
ventricular dilation, and past research has demonstrated that CSF
biomarker changes in amyloid precede CSF biomarker changes
in tau during the typical presentation of AD (Jack et al., 2013).
Therefore, one possibility is that neural vulnerability due to
ceramide levels may lead to an amyloid specific neurodegenera-
tive process early in the disease process that is then compounded
by a tau-specific neurodegenerative process later on. In such a
scenario, a later starting point in an individual’s disease course
(when the paritcipant has both tau and amyloid pathology) could
be associated with an increased rate of decline relative to non-risk
groups (as in Figure 2), but may at that stage be a more tau-based
process that would not be as impacted by a genetic predisposition
toward higher levels of ceramides. Additional work following the
course of neurodegenerative processes in relation to the course
of CSF biomarker changes will be necessary to better understand
how individual variability in genetic risk modifies this complex
association.
SNP MODIFICATION OF THE RELATION BETWEEN TAU AND
NEURODEGENERATION
The primary SNP associated with neurodegeneration in individ-
uals with tau pathology was rs12261764 annotated to WDR11
antisense RNA 1 (WDR11-AS1). In the hapmap sample, this SNP
is in strong LD with rs122527599 (R2 = 0.98, D′ = 1), which
has been shown to be an enhancer in fetal brain tissue (Ward
and Kellis, 2012). WDR11 has been shown to interact with the
transcription factor EMX1 leading to impaired development of
olfactory neurons within individuals with Kallmann syndrome
(Kim et al., 2010). There has been some indication of the presence
of both tau and amyloid protein deposits in the olfactory bulb
of individuals with AD (Mundiñano et al., 2011). It is unclear
how such pathology might relate to the neurodegenerative cas-
cade, or how the observed genetic interaction may modify such
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FIGURE 5 | WDR11-AS1 (rs12261764) interaction is consistent between
datasets. ADNI-1 data are presented in the top panel and ADNI-2/GO data
are presented in the bottom panel. Biomarker groups are presented on the
x-axis and annual change in the left inferior lateral ventricle is presented on
the y-axis. Boxplots are grouped by rs12261764. G is the minor allele. The
tau × rs7849530 interaction was statistically significant in both datasets
(p ≤ 0.001). In ADNI-1, tau positive homozygous carriers of the G allele
showed a greater rate of ventricular dilation than tau positive carriers of
the T allele (p < 0.05), and the same trend was present in ADNI-2/GO
(p = 0.059).
Table 3 | Hierarchical linear regression results.
rs7849530 Change statistics
Model AIC R2 Adj. R2 Adj. R2 change Adj. R2 change 95% CI# F change df1 df2 Sig. F Change (P-value)
1a 8463 0.360 0.352 0.352 [0.30–0.39] 47.87 8 681 3.29 ×10−61
2b 8462 0.363 0.354 0.002 [−0.001–0.013] 2.83 1 680 0.092
3c 8442 0.382 0.373 0.019 [0.004–0.043] 21.83 1 679 4.00 ×10−6
4d 8444 0.384 0.373 0.000 [−0.001–0.005] 0.788 2 677 0.455
5e 8406 0.419 0.408 0.035 [0.011–0.070] 40.798 1 676 3.14 ×10−10
a Predictors: Constant, Intracranial Volume, Age, Education, Diagnosis, Gender, Biomarker Group.
b Predictors: Constant, Intracranial Volume, Age, Education, Diagnosis, Gender, Biomarker Group, APOE.
c Predictors: Constant, Intracranial Volume, Age, Education, Diagnosis, Gender, Biomarker Group, APOE, rs7849530.
d Predictors: Constant, Intracranial Volume, Age, Education, Diagnosis, Gender, Biomarker Group, APOE, rs7849530, rs7849530 × Tau_only, rs7849530 × Both.
e Predictors: Constant, Intracranial Volume, Age, Education, Diagnosis, Gender, Biomarker Group, eAPOE, rs7849530, rs7849530 × Tau_only, rs7849530 × Both,
rs7849530 × Amyloid_only.
# Ninety five percentage confidence interval calculated using a bootstrap procedure with 1000 replicates.
an association, but it provides an interesting target for future
functional analyses.
STRENGTHS ANDWEAKNESSES
The present manuscript provides evidence of multiple novel SNP
× biomarker interactions in conferring risk or resilience from
neurodegeneration. The joint analysis of the combined dataset
allowed us to maximize our power (Skol et al., 2006), and
the stratified post-hoc analyses provided support for the consis-
tency of the observed effects across data sources. However, this
manuscript is not without limitations. Although consistent effects
were observed, a true replication sample from an external data
Frontiers in Aging Neuroscience www.frontiersin.org August 2014 | Volume 6 | Article 183 | 8
Hohman et al. Genetic modification of neurodegeneration
source with GWAS and PET data will be necessary to confirm our
findings. We did observe differences in effect size between ADNI-
1 and ADNI-2/GO, likely due to the difference in follow-up time.
It is also possible that differences in CSF batches between ADNI-
1 and ADNI-2/GO could be driving the differences in effect size
between the two groups. In the current analysis, it is difficult
to distinguish batch effects from group differences because we
used the first CSF observation for each subject (thus the batches
align roughly with ADNI-1 subjects vs. ADNI-2/GO subjects).
However, it should be noted that previous work has demonstrated
the test-retest reliability of the biomarker measures from CSF in
the ADNI dataset (Shaw et al., 2011). The proposed mechanisms
also assume a strong association between CSF biomarker levels
and levels of neuropathology (Clark et al., 2003; Strozyk et al.,
2003). Future analyses will build on this finding by evaluating
the observed interactions in an autopsy sample where a more
direct relationship between genotype, gene expression, and AD
pathology can be assessed.
In the present analysis we did not have a large enough sam-
ple to meaningfully assess gene-biomarker interactions across
diagnostic groups. Our observed effects appeared to show simi-
lar trends across the diagnostic categories (Supplemental Figures
2, 3); however given the known differences in the relationship
between brain volume and CSF biomarkers across diagnostic
categories, it would be worthwhile to pursue gene-biomarker-
diagnosis interactions, if a larger sample could be acquired.
An additional independent sample with a comparable longi-
tudinal follow-up interval to that of ADNI-1 could help clar-
ify whether the cohort differences observed are simply due to
differences in power, or rather such differences were due to
batch effects, MRI follow-up interval, or sample characteristics.
Moreover, future work replicating our findings in an independent
sample with MRI, CSF, and genotype data is needed to confirm
the observed effects. Finally, to avoid possible confounding factors
related to population substructure we chose to restrict all analyses
to Caucasian individuals, and thus our results may not generalize
to other ancestral populations. We believe the statistical approach
taken provides a blue-print for future gene-environment interac-
tion analyses aimed at identifying genetic modifiers of known AD
risk factors.
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